Date: 2015-04-21
Type of information: Collaboration agreement
Compound: malaria vaccine candidates
Company: Genvec (USA - MD) Laboratory of Malaria Immunology and Vaccinology (LMIV) (USA)
Therapeutic area: Infectious diseases - Parasitic diseases
Type agreement: collaboration R&D
Action mechanism: vaccine
Disease: malaria
Details: * On April 21, 2015, GenVec announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. The research collaboration will utilize GenVec's proprietary gorilla adenovirus vectors to deliver a number of novel antigens discovered at the LMIV in order to create and test a variety of malaria vaccine candidates. GenVec will construct vaccine candidates at its laboratories and hand them off to LMIV's Vaccine Development Unit, which is headed by Patrick E. Duffy, M.D., for preclinical testing. The focus of this joint approach is to devise vaccines that block the transmission of Plasmodium falciparum by triggering the production of antibodies that are taken up by a mosquito when it bites a vaccinated individual. This differentiated approach launches an attack on the parasite while it is in its mosquito carrier and could potentially help stop the spread of the disease to subsequent bite victims.
Financial terms:
Latest news:
